Profil
Murty Bosukonda is the founder of Thrasos Therapeutics, Inc. which was founded in 2003.
Currently, he holds the position of Executive Director at Thrasos, Inc.
Aktive Positionen von Murty Bosukonda
| Unternehmen | Position | Beginn |
|---|---|---|
Thrasos, Inc.
 Thrasos, Inc. Pharmaceuticals: MajorHealth Technology Thrasos, Inc. discovers and develops drugs. The company develops protein mimetic compounds for Kidney and Heart disease. Thrasos is headquartered in Hopkinton, MA | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Murty Bosukonda
| Unternehmen | Position | Ende |
|---|---|---|
Thrasos Therapeutics, Inc.
 Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Thrasos, Inc.
Thrasos, Inc. Pharmaceuticals: MajorHealth Technology Thrasos, Inc. discovers and develops drugs. The company develops protein mimetic compounds for Kidney and Heart disease. Thrasos is headquartered in Hopkinton, MA | Health Technology |
Thrasos Therapeutics, Inc.
Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada. | Health Technology |
